Young Innovators of Medicines

younginnovatorsofmedicines.nl

The Young Innovators of Medicines form the youth branch of the Innovative Medicines Association. This is a trade association for 44 drug companies with a Dutch branch. The youth branch was founded in 2013, under the then name Jong Nefarma. The members of the Association have put forward 22 high potentials to participate in the youth department. In recent years, young people themselves have defined themes such as talent and development, partnership with other young (care) associations, connecting young people within the Association, and debate and advice on important topics in the pharmaceutical industry.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research

NANOFORM RELEASES NEXT-GENERATION AI-BASED DRUG SELECTION TOOL

Nanoform | March 23, 2021

news image

Nanoform innovative nanoparticle medicine enabling company next generation of its STARMAP® AI artificial intelligence platform nanoparticle bioavailability excipient microns nm CESS technology silico pharma drugs lifecycle managementNanoform, an innovative nanoparticle medicine enabling company, has today dispatched the next generation of its STARMAP® AI (artificial intelligence) platform, v2.0. The technology uses scanty information AI to expand trial results from its CESS® nanopart...

Read More

PHARMA TECH

FORTREA SELECTS COGNIZANT AS ITS TECHNOLOGY TRANSFORMATION PROVIDER

PR Newswire | January 05, 2024

news image

Cognizant and Fortrea, a leading global provider of clinical development and patient access solutions to the life sciences industry, today announced that Cognizant has been selected as Fortrea's strategic technology transformation provider. By partnering with Cognizant, Fortrea aims to continue advancing its mission and delivering solutions to its pharmaceutical, biotechnology and medical device customers – and to the patients those customers serve – within the c...

Read More

Business Insights

VIRPAX PHARMACEUTICALS ENGAGES TORREYA CAPITAL TO ADVISE ON GLOBAL PARTNERING EFFORTS

Torreya Capital, Virpax Pharmaceuticals | April 23, 2021

news image

Virpax® Pharmaceuticals, Inc. reported today that it has appointed Torreya Capital, LLC as the Company's sole financial adviser for its partnering and licensing activities in strategic global markets. Torreya is a leading investment bank that has supported more than $100 billion in life sciences transactions since its establishment in 2007. “We are thrilled to be collaborating with Torreya to extend our partnerships in key markets,” said Anthony ...

Read More

Business Insights

ABCELLERA AND EMPIRICO EXPAND STRATEGIC MULTI-TARGET ANTIBODY DISCOVERY COLLABORATION

AbCellera | May 04, 2022

news image

AbCellera and Empirico Inc. announced today that they have expanded their strategic multi-target discovery collaboration, which leverages Empirico’s Precision Insights PlatformTM to discover genetically validated drug targets and AbCellera’s technology to identify lead candidate antibodies against those targets. Following the rapid progress of their first collaborative program, which identified a lead candidate against an undisclosed G protein-coupled receptor target in less than 12 ...

Read More
news image

Research

NANOFORM RELEASES NEXT-GENERATION AI-BASED DRUG SELECTION TOOL

Nanoform | March 23, 2021

Nanoform innovative nanoparticle medicine enabling company next generation of its STARMAP® AI artificial intelligence platform nanoparticle bioavailability excipient microns nm CESS technology silico pharma drugs lifecycle managementNanoform, an innovative nanoparticle medicine enabling company, has today dispatched the next generation of its STARMAP® AI (artificial intelligence) platform, v2.0. The technology uses scanty information AI to expand trial results from its CESS® nanopart...

Read More
news image

PHARMA TECH

FORTREA SELECTS COGNIZANT AS ITS TECHNOLOGY TRANSFORMATION PROVIDER

PR Newswire | January 05, 2024

Cognizant and Fortrea, a leading global provider of clinical development and patient access solutions to the life sciences industry, today announced that Cognizant has been selected as Fortrea's strategic technology transformation provider. By partnering with Cognizant, Fortrea aims to continue advancing its mission and delivering solutions to its pharmaceutical, biotechnology and medical device customers – and to the patients those customers serve – within the c...

Read More
news image

Business Insights

VIRPAX PHARMACEUTICALS ENGAGES TORREYA CAPITAL TO ADVISE ON GLOBAL PARTNERING EFFORTS

Torreya Capital, Virpax Pharmaceuticals | April 23, 2021

Virpax® Pharmaceuticals, Inc. reported today that it has appointed Torreya Capital, LLC as the Company's sole financial adviser for its partnering and licensing activities in strategic global markets. Torreya is a leading investment bank that has supported more than $100 billion in life sciences transactions since its establishment in 2007. “We are thrilled to be collaborating with Torreya to extend our partnerships in key markets,” said Anthony ...

Read More
news image

Business Insights

ABCELLERA AND EMPIRICO EXPAND STRATEGIC MULTI-TARGET ANTIBODY DISCOVERY COLLABORATION

AbCellera | May 04, 2022

AbCellera and Empirico Inc. announced today that they have expanded their strategic multi-target discovery collaboration, which leverages Empirico’s Precision Insights PlatformTM to discover genetically validated drug targets and AbCellera’s technology to identify lead candidate antibodies against those targets. Following the rapid progress of their first collaborative program, which identified a lead candidate against an undisclosed G protein-coupled receptor target in less than 12 ...

Read More